Sleep Apnea Notification Feature (SANF)

The Apple Sleep Apnea Notification Feature (SANF) is an over-the-counter, software-only mobile medical application designed for risk assessment of moderate-to-severe sleep apnea in undiagnosed adults aged 18 and over, utilizing Apple Watch sensor data. Its methodology involves analyzing sensor patterns for breathing disturbances, with its scientific validation based on a clinical study demonstrating specific sensitivity and specificity metrics, and it operates under an FDA-approved predetermined change control plan.

On September 13, 2024, the U.S. Food & Drug Administration completed its review of Apple Inc.'s Sleep Apnea Notification Feature (SANF), an over-the-counter software-only mobile medical application intended to assess the risk of moderate-to-severe sleep apnea. Determined to be substantially equivalent to previously marketed devices, SANF analyzes Apple Watch sensor data to identify breathing disturbance patterns, providing notifications to users aged 18 and over who have not been previously diagnosed. It is crucial to note that the feature is not intended for the diagnosis, treatment, or management of sleep apnea, serving solely as a risk assessment tool. The FDA's determination was based on comprehensive non-clinical and clinical testing, including software verification and validation, cybersecurity evaluations, human factors validation, and platform compatibility. A prospective clinical study involving 1,499 subjects validated the feature's performance, demonstrating a sensitivity of 66.3% and a specificity of 98.5% for detecting moderate-to-severe sleep apnea. The review also encompassed approval of a Predetermined Change Control Plan, which outlines a framework for future software modifications—such as algorithm adjustments or notification logic changes—without requiring a new submission, provided they adhere to defined protocols and do not alter the device's safety, effectiveness, or intended use.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. Given the device's 'risk assessment' purpose and specific performance metrics, what are the recommended clinical pathways for users who receive a notification of potential moderate-to-severe sleep apnea?; How does the SANF algorithm specifically process Apple Watch sensor data to identify patterns indicative of breathing disturbances, and what specific physiological parameters are prioritized?; What are the potential implications of the 66.3% sensitivity on false negatives, and how might this impact individuals who truly have sleep apnea but are not notified?; Does the Predetermined Change Control Plan include provisions for re-validating the algorithm's performance if there are significant changes in Apple Watch hardware or new sensor capabilities?; Are there any plans for post-market surveillance or real-world evidence collection to assess the long-term impact of SANF on user behavior, diagnostic rates, or overall public health outcomes related to sleep apnea?